Merck & Co.
United States
4005 articles about Merck & Co.
-
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
5/3/2023
Merck, known as MSD outside of the United States and Canada, announced that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 8:40 a.m. PDT / 11:40 a.m. EDT.
-
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
4/28/2023
Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee, by a vote of 11 to 1 with one abstention, supported FDA approval of LYNPARZA plus abiraterone and prednisone or prednisolone for the first-line treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.
-
Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
-
Merck Announces First-Quarter 2023 Financial Results
4/27/2023
First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines.
-
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
-
Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.
-
The checkpoint inhibitor improved patient outcomes in three cancer trials, according to results presented at the AACR meeting.
-
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
-
Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, picking up a mid-stage ulcerative colitis and Crohn's asset.
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
4/16/2023
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy for the first-line treatment of patients with advanced or unresectable biliary tract cancer.
-
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
4/16/2023
Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
-
Liver toxicities triggered a partial clinical hold on Merck KGaA's trial studying its BTK inhibitor candidate for multiple sclerosis.
-
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
4/13/2023
Merck announced the U.S. FDA has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
4/12/2023
Microbiotica today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).
-
Merck Named One of Fortune’s 2023 100 Best Companies to Work For(R)
4/11/2023
Merck, known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years.
-
Results from two late-stage trials showed the Merck-Eisai combo treatment failed to boost survival in two difficult-to-treat advanced cancers.
-
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
4/7/2023
Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
-
MRNA-4157/V940 in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the EMA for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
4/6/2023
Moderna, Inc. and Merck announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.
-
Proxygen added Merck to its partner roster on Wednesday, garnering an undisclosed upfront payment plus a potential $2.55 billion in milestones.
-
Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors
4/5/2023
Simcha Therapeutics (“Simcha”) today announced a clinical trial collaboration with Merck (known as MSD outside the US and Canada) to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.